Brandon Carter

Massachusetts Institute of Technology — United States

Physics and Astronomy · Physical Sciences

40h-index8.9kcitations189works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cosmology and Gravitation Theories(61), Black Holes and Theoretical Physics(48), Pulsars and Gravitational Waves Research(26), Quantum, superfluid, helium dynamics(21), Ubiquitin and proteasome pathways(19)

Publications189 total

T-cell receptors that are k-binding have defined sequence features
Frontiers in Immunology·2025Open Access
Dynamic Crypto-Behavioral Profiling for Autonomous Ransomware Detection
2024· 1 citedOpen Access
Machine learning model interpretations explain T cell receptor binding
2023· 2 citedOpen Access
Supplementary Figure 3 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Data from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Table 1 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Figure 2 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Figure 2 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Figure 5 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Data from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Methods, Figure Legends 1-6 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Methods, Figure Legends 1-6 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Figure 1 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Figure 4 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Figure 4 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Table 1 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Figure 1 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Figure 5 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Figure 3 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
Supplementary Figure 6 from The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA
2023Open Access
page 1 of 10Next →

Frequent Co-authors

B. J. Carr(4), David K. Gifford(4), David Langlois(3), Maxwell L. Bileschi(2), Drew Bryant(2), Theo Sanderson(2), D. Sculley(2), Mark A. DePristo(2), Lucy J. Colwell(2), Frank Wilczek(2), Anne-Christine Davis(2), D.M. Barbano(2), M.A. Drake(2), Patrick Peter(2), Jean–Philippe Uzan(2), David Belanger(1), Alex Bateman(1), Jerome Giuseffi(1), Benjamín Felson(1), H. Quintana(1)